Savvas Petrogiannis

Dr. Savvas Petrogiannis


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in Medicina
Verified
Journal Article
Open access
PDF file
NPNikos Petrogiannis
Nikos Petrogiannis
MFMaria Filippa
Maria Filippa
KCKalliopi Chatzovoulou
Kalliopi Chatzovoulou
SPSavvas Petrogiannis
Savvas Petrogiannis
IFIoannis Filippas
Ioannis Filippas
KCKaterina Chatzimeletiou
Katerina Chatzimeletiou
Advancements in assisted reproductive technologies (ARTs) have led to the development of various add-on techniques aimed at improving oocyte quality and enhancing embryo implantation potential. These techniques target critical stages of both oocyte and embryo physiology, including oocyte growth and maturation, fertilization, chromosomal status, and embryo development. Key approaches involve the optimization of in vitro fertilization (IVF) protocols, recruiting capable follicles giving rise to dynamic oocytes to evolve, culture media supplementation, preimplantation genetic testing (PGT), and mitochondrial replacement therapy (MRT), all of which are designed to enhance oocyte competence through its function and metabolism. The use of PGT has been promising in selecting embryos suitable for transfer, thus optimizing implantation success. Emerging technologies, such as platelet-rich plasma treatment (PRP), time-lapse imaging (TLI), and hyaluronan-rich (HA) culture media, claim to improve ovarian rejuvenation and uterine receptivity, embryo selection, as well as embryo implantation potential, respectively. Evidence for certain add-on approaches remains limited, but ongoing research suggests that the use of such treatments may lead to increased clinical pregnancies and live birth rates, especially in poor-prognosis patients. The present review describes the current state of the add-on innovations, their mechanisms of action, as well as their possibilities to increase ART success rates.

Verified
Journal Article
Open access
PDF file
Dimitrios PapageorgiouDimitrios Papageorgiou
Dimitrios Papageorgiou
Vasileios KallesVasileios Kalles
Vasileios Kalles
Vasilios PergialiotisVasilios Pergialiotis
Vasilios Pergialiotis
Ioannis K. PapapanagiotouIoannis K. Papapanagiotou
Ioannis K. Papapanagiotou
NTNikolaos Tasis
Nikolaos Tasis
ISIOAKEIM SAPANTZOGLOU
IOAKEIM SAPANTZOGLOU
Background/Objectives: Peritoneal metastases from breast cancer (PMBC) are rare, aggressive, and lack standardized management. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a potential locoregional strategy for highly selected patients. This PRISMA-informed narrative review used a structured and reproducible search and study-selection process, SWiM-guided narrative synthesis, and descriptive pooled individual-patient data (IPD) analysis to evaluate the feasibility, safety, and reported oncologic outcomes of CRS plus HIPEC in PMBC. Methods: The English-language literature was searched in PubMed/MEDLINE, Embase, and Google Scholar up to 31 December 2025. Eligible peer-reviewed full-text articles reported PMBC patients treated with CRS plus HIPEC and at least one perioperative or oncologic outcome. Patient-level data were extracted when explicitly reported and were summarized descriptively; no inferential survival analysis was performed. Risk of bias was assessed using JBI checklists for case reports/series and ROBINS-I for the multicenter cohort. Results: Six peer-reviewed studies were included (66 PMBC patients); 30 patients underwent CRS plus HIPEC. Five studies provided sufficient patient-level data for descriptive pooled IPD analysis (n = 17). Median age at CRS/HIPEC was 56 years (n = 13 with reported age), and the median interval between breast cancer diagnosis and PMBC was 12 years (range 0–30 years; available-case analysis). Median PCI was 21.5 (n = 16), and complete cytoreduction (CC-0) was achieved in 9 of 17 patients. Major postoperative morbidity occurred in 17.6%, while no in-hospital or 30-day mortality was reported. Reported disease-control and survival outcomes were heterogeneous and are therefore summarized only descriptively. In the multicenter cohort, curative-intent CRS with or without HIPEC was associated with a median overall survival of 61.5 months measured from diagnosis of peritoneal metastases; however, HIPEC-specific baseline characteristics and oncologic outcomes were not separately stratified. Conclusions: CRS plus HIPEC appears feasible in highly selected PMBC patients and may be associated with favorable outcomes when complete cytoreduction is achievable. However, the evidence is sparse, heterogeneous, and highly prone to selection and publication bias. Therefore, no causal inference regarding the independent benefit of HIPEC can be drawn, and this approach should be considered investigational pending prospective multicenter registries.

29 May 2026 in Medicina
Verified
Journal Article
Open access
PDF file
Dimitrios PapageorgiouDimitrios Papageorgiou
Dimitrios Papageorgiou
Vasilios PergialiotisVasilios Pergialiotis
Vasilios Pergialiotis
Ioannis K. PapapanagiotouIoannis K. Papapanagiotou
Ioannis K. Papapanagiotou
EZEleftherios Zachariou
Eleftherios Zachariou
NPNikolaos Plevris
Nikolaos Plevris
KKKonstantinos Kontzoglou
Konstantinos Kontzoglou
Background and Objectives: Robotic-assisted tubal reanastomosis (RATR) remains a clinically relevant option for selected women seeking fertility after sterilization. In the era of IVF, surgical reversal continues to be discussed because it may restore the possibility of spontaneous conception rather than offering only cycle-dependent treatment. However, the available evidence on RATR is heterogeneous and derives predominantly from observational studies. The aim of this narrative review with a structured literature search was to synthesize the published evidence on the operative, reproductive, and economic outcomes of RATR and to contextualize its role in contemporary fertility counseling. Materials and Methods: A structured literature search of PubMed/MEDLINE, Scopus, and Google Scholar was performed from database inception to 20 December 2025. Data were synthesized descriptively without meta-analysis. Primary robotic clinical studies were interpreted separately from secondary and contextual publications. Results: In total, 16 studies were included in our study. The evidence base comprised predominantly retrospective cohorts and case series; no randomized controlled trials were identified. Reported tubal patency endpoints in robotic cohorts ranged from 81.0% to 94.1%, although denominators differed across studies and were reported either per patient or per tube. Reported pregnancy outcomes ranged from 25% to 80%, reflecting substantial heterogeneity in patient selection, follow-up duration, and outcome definitions. When woman-level delivery or live-birth outcomes were explicitly reported, they were generally encouraging in selected series, although not uniformly defined. Estimated blood loss was usually minimal when reported, and conversion to laparotomy was uncommon. Any comparison with IVF was indirect because no contemporary head-to-head comparative studies were identified. Economic data were sparse, institution-specific, and methodologically heterogeneous. Conclusions: Available observational evidence suggests that RATR is a feasible minimally invasive option for fertility restoration in carefully selected women after sterilization. However, the evidence base remains limited by retrospective design, small cohorts, heterogeneous outcome reporting, variable follow-up, and indirect comparison with IVF. RATR should be considered within individualized fertility counseling rather than as a universal alternative to IVF. Prospective comparative studies with standardized outcome definitions, transparent reporting of prognostic factors, and robust economic evaluation are needed.